Search
Praziquantel
go.drugbank.com/drugs/DB01058ApprovedInvestigationalVet approved[A263201] The efficacy of praziquantel in treating parasitic flatworms infection with low cost (~US$0.20 drug cost to treat a child) makes it an integral to WHO's plan to eliminate schistosomiasis by 2030
Linaclotide
go.drugbank.com/drugs/DB08890ApprovedInvestigationalLinaclotide was first approved by the FDA on August 30, 2012.[A260271] It gained EMA and Health Canada approval on November 26, 2012 [L47216] and December 3, 2013,[L47221] respectively.
Netilmicin
go.drugbank.com/drugs/DB00955ApprovedNetilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. … Netilmicin inhibits protein synthesis in susceptible organisms by binding to the bacterial 30S ribosomal subunit and interfering with mRNA binding and the acceptor tRNA site.
Lacosamide
go.drugbank.com/drugs/DB06218ApprovedInvestigational[A262681] Lacosamide was first approved by the European Commission in August 2008 and was later approved by the FDA in October 2008. … [A262681] It was granted approval by Health Canada in September 2010.[L49206]
Rezafungin
go.drugbank.com/drugs/DB16310ApprovedInvestigationalIt can only be administered intravenously but does not reach therapeutic concentrations in the central nervous system, eye and urine.
rCFP-10
go.drugbank.com/drugs/DB21907ApprovedrCFP-10 is a recombinant culture filtrate protein of Mycobacterium tuberculosis used as an ingredient in the diagnostic agent SIILTIBCY along with rdESAT-6.
Dinoprostone
go.drugbank.com/drugs/DB00917ApprovedInvestigationalIt also stimulates osteoblasts to release factors which stimualtes bone resorption by osteoclasts.
Fosphenytoin
go.drugbank.com/drugs/DB01320ApprovedInvestigationalIt works by slowing down impulses in the brain that cause seizures.
AN0128
go.drugbank.com/drugs/DB05054InvestigationalAN0128 is a good candidate for a topical antibiotic and is currently being developed by Anacor as a novel therapeutic for acne and atopic dermatitis.
Asparaginase Escherichia coli
go.drugbank.com/drugs/DB00023ApprovedInvestigationalAsparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia … Therapeutic L-asparaginase from _E. coli_ works by depleting the levels of non-essential amino acid, asparagine, in lymphoblastic leukemic cells thus promoting apoptotic cell death [A31999].